Navigation Links
NeuroVive Admitted to Trading on NASDAQ OMX Stockholm
Date:3/25/2013

LUND, Sweden, March 25, 2013 /PRNewswire/ --

NeuroVive, a leading mitochondrial medicine company, announces that its shares have been approved for listing on NASDAQ OMX Stockholm by the exchange's Listing Committee. The first day of trading on NASDAQ OMX Stockholm will be April 10th and the last day of trading on the Swedish trading platform AktieTorget will be April 9th.

The stock will be traded under the same ticker symbol, NVP. No new shares will be issued in conjunction with the listing on NASDAQ OMX Stockholm.

Mikael Bronnegard, CEO of NeuroVive Pharmaceutical said: "Our move to NASDAQ OMX Stockholm is an important step forward in the growth and development of our company. Through this listing NeuroVive will gain access to a broader and deeper pool of investors that will be vital as we look to finance our strategy which is designed to maximize shareholder value from our leading position in mitochondrial medicine."

About NeuroVive Pharmaceutical AB (publ)

NeuroVive Pharmaceutical AB (http://www.neurovive.com) a leading mitochondrial medicine company is developing a portfolio of products to treat acute cardiovascular and neurological conditions through mitochondrial protection.

NeuroVive's products are based on the cyclophilin inhibitor, cyclosporine, and work by preventing the death of mitochondria in distressed cells and the subsequent cascade of intracellular biochemical events that lead to secondary tissue damage following an acute cardiac or traumatic brain injury.

NeuroVive's lead product is CicloMulsion®, the first cyclophilin inhibitor for the treatment of reperfusion injuries following cardiac stenting. CicloMulsion® is currently in a 1000 patient Phase III clinical trial evaluating its ability to reduce reperfusion injuries in patients with myocardial infarction.

NeuroVive is also developing NeuroSTAT®, a cyclophilin inhibitor, which is entering a Phase IIa clinical trial in patients with severe traumatic brain injury. Both indications have huge medical need and for which there are currently no approved pharmaceutical treatment options. Both CicloMulsion® and NeuroSTAT® are special formulations of cyclosporine for use in acute cardiac and brain injury indications.

NeuroVive's pipeline includes novel cyclophilin inhibitors, and drug candidates that act on mitochondria to address energy regulation disorders.

NeuroVive´s shares are listed on the Swedish trading platform AktieTorget (http://www.aktietorget.se). The AktieTorget market is focused on emerging, entrepreneurial businesses through an electronic trading system supplied by the OMX Nordic stock exchange in Stockholm, Sweden.

Media and investor relations contacts
NeuroVive Pharmaceutical: Mikael Bronnegard
Email: info@neurovive.com
Phone No: +46(0)70-299-62-64

Citigate Dewe Rogerson: Nina Enegren / David Dible
Email: nina.enegren@citigatedr.co.uk
Phone No: +44(0)207-282-1050


'/>"/>
SOURCE NeuroVive
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. NeuroVive Acquires Highly Potent, Novel Cyclophilin Inhibitors From Biotica
2. NeuroVive Appoints Chief Operating Officer
3. Sihuan Pharmaceutical Collaborates with NeuroVive to Develop Two Innovative Cardio-cerebral Vascular Products in China
4. PAREXEL International Provides Update On Share Repurchase Program, Announces A New $50 Million Accelerated Share Repurchase Agreement And A New $50 Million 10b5-1 Trading Plan
5. Trading of Depomed Common Stock Halted
6. Vasomedical Common Stock Commences Trading on the OTCBB
7. MetaStat Announces Stock Trading on OTC Bulletin Board
8. SafeCode Drug Technologies Corp. Begins Trading on the Over-the-Counter Bulletin Board
9. Generex Addresses Recent Trading Volume in Shares of its Common Stock
10. Sae-A Trading Sponsors Medical Mission to Haiti
11. Angeion Announces Name Change and New Trading Symbol Effective Tuesday, August 21, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... -- AOTI Inc. announced today that its fully owned USA ... New York City Office in Yonkers, New York ... Oxygen (TWO 2 ) homecare therapy. This new East Coast location ... (ACHC) under the company,s DMEPOS accreditation for Home/Durable Medical Equipment Services. ... Advanced Oxygen Therapy Inc. ...
(Date:8/10/2017)... -- Physical Rehabilitation Network (PRN), acquired the long-standing outpatient rehabilitation clinic, ... . The reputable clinic will continue to be co-owned and ... staff of four clinicians. Lipkin received his doctorate in physical ... years of experience with a strong background in manual therapy. ... 10th PRN clinic in and around the Denver ...
(Date:8/7/2017)... 7, 2017 Insightin Health, provider of ... and engagement, announced the selection of Michael ... Development, effective as of February 2017. In this role, ... strategy for our clients. Wood brings with him ... and business analytics within the healthcare industry. Wood ...
Breaking Medicine Technology:
(Date:8/23/2017)... ... August 23, 2017 , ... MobilityWorks ®, ... named to the 2017 Inc. 500|5000, an exclusive ranking of America’s fastest-growing private ... of 139 percent, marking the twelfth year that the company has been included ...
(Date:8/23/2017)... ... August 23, 2017 , ... The non-profit ... holding an inaugural State of the Science Symposium in partnership with the Global ... 2017. , This symposium provides a forum for global leaders in human nutrition ...
(Date:8/22/2017)... , ... August 22, 2017 , ... ... pleased to announce the addition of Zack Tisch as the firm’s new Consulting ... KLAS-ranked healthcare IT consulting firm’s national accounts, from assisting clients with initial vendor ...
(Date:8/22/2017)... ... August 22, 2017 , ... “To Walk Away”: ... a B17 bomber named Edward Koontz. “To Walk Away” is the creation of published ... has published over two hundred manuscripts in chemistry and religion, as well as four ...
(Date:8/22/2017)... ... August 22, 2017 , ... ... the Founder and Managing Member for t4 Leadership Development & Consulting. He has ... his definition of “success”: physician leadership development, servant leadership, data driven process improvement, ...
Breaking Medicine News(10 mins):